# US 2020/0392198 A1 · Peptide dual agonists of gipr and glp2r

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392198 A1
- Document ID: US20200392198A1
- Status: Published application
- Kind: A1
- Application number: 17/007,407
- Filed: 2020-08-31
- Published: 2020-12-17
- Earliest claimed: 2016-10-12
- Assignees: University of Copenhagen
- Applicants: University of Copenhagen
- Inventors: Bolette Hartmann; Maria Buur Nordskov Gabe; Lærke Smidt Gasbjerg; Mette Marie Rosenkilde; Jens Juul Holst
- Web page: https://patentgrep.com/patent/US20200392198A1

## CPC

- C07K 14/645: Secretins
- C12N 15/62: DNA sequences coding for fusion proteins
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- C07K 14/605: Glucagons
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.

## Claims

### Claim 1

A peptide dual agonist of the GIPR (glucose-dependent insulinotropic polypeptide receptor) and of the GLP2R (glucagon-like peptide-2 receptor), said peptide comprising
(SEQ ID NO: 21)
HX20X21GTFISDYSTILDNLAARDFX22NWLX23X24X25KX26X27X28,
where X20 is selected from A, V and G,
X21 is selected from D and E,
X22 is selected from I and V,
X23 is selected from I and L,
X24 is selected from Q and A,
X25 is selected from T and Q,
X26 is selected from I and G,
X27 is selected from T and K, and
X28 is selected from D and K,
or a functional variant thereof having 1, 2, 3 or 4 individual amino acid substitutions, wherein said functional variant comprises substitution of 0, 1, or 2 of amino acids 5 to 11 of SEQ ID NO:21, and wherein said functional variant binds to and activates the GIPR and the GLP-2R.

### Claim 2 (depends on 1)

The peptide dual agonist according to claim 1, wherein said peptide comprises a sequence selected from the group consisting of:
a)
(SEQ ID NO: 11)
HGDGTFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 13)
HADGTFSSDYSTILDNLAARDFINWLIQTKITD,
and a functional variant of either thereof having 1 or 2 individual amino acid substitutions;
b)
(SEQ ID NO: 3)
HADGTFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 4)
HAEGSFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 6)
HAEGTFISDMNTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 12)
HVDGTFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 14)
HADGTFIDDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 15)
HADGTFISEYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 26)
HADGTFSSDYSTILDNLAAKDFINWLIQTKITD,
and a functional variant of any thereof having 1, 2 or 3 individual amino acid substitutions;
c)
(SEQ ID NO: 1)
HAEGTFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 2)
HAEGTFISDYSTILDNLAARDFINWLIQTKITDNDWKHNITQ,
(SEQ ID NO: 16)
HADGTFISDYSTILDNLAARDFINWLIQTKGTD,
(SEQ ID NO: 17)
HADGTFISDYSTILDNLAARDFINWLIQTKIKD,
(SEQ ID NO: 18)
HADGTFISDYSTILDNLAARDFINWLIQTKITK,
and a functional variant of any thereof having 1, 2, 3 or 4 individual amino acid substitutions;
d)
(SEQ ID NO: 27)
HADGTFISDYSKILDNLAARDFINWLIQTKITK,
(SEQ ID NO: 28)
HADGTFISDYSTIKDNLAARDFINWLIQTKITK,
(SEQ ID NO: 29)
HADGTFISDYSTILDKLAARDFINWLIQTKITK,
(SEQ ID NO: 30)
HADGTFISDYSTILDNLKARDFINWLIQTKITK,
(SEQ ID NO: 31)
HADGTFISDYSTILDNLAAKDFINWLIQTKITK,
(SEQ ID NO: 32)
HADGTFISDYSTILDNLAARDFINWLIQTKGKKNDWKHNITQ,
and a functional variant of any thereof having 1, 2, 3, 4 or 5 individual amino acid substitutions; and
e)
(SEQ ID NO: 7)
HAEGTFISDYSIAMDKLAARDFINWLIQTKITD
(SEQ ID NO: 8)
HAEGTFISDYSTILDNIHQQDFINWLIQTKITD
(SEQ ID NO: 9)
HAEGTFISDYSTILDNLAARDFVNWLLAQKITD,
(SEQ ID NO: 10)
HAEGTFISDYSTILDNLAARDFINWLIQTKGKK,
(SEQ ID NO: 19)
HADGTFISDYSTILDNLAARDFINWLIQTKGKK,
and a functional variant of any thereof having 1, 2, 3, 4, 5 or 6 individual amino acid substitutions,
wherein said functional variant of any thereof comprises substitution of 0, 1, or 2 of amino acids 5 to 11 of SEQ ID NO:21, and wherein said functional variant binds to and activates the GIPR and the GLP-2R.

### Claim 3 (depends on 1)

The peptide dual agonist according to claim 1, wherein said peptide further comprises additional amino acids at the C-terminus.

### Claim 4 (depends on 3)

The peptide dual agonist according to claim 3, wherein said additional amino acids comprises NDWKHNITQ (SEQ ID NO.25), or a variant or fragment of SEQ ID NO:25.

### Claim 5 (depends on 1)

The peptide dual agonist according to claim 1, wherein said peptide is modified by attaching at least one fatty acid molecule at one or more amino acid residues of any one of SEQ ID NOs: 21-19 and 26-32.

### Claim 6 (depends on 5)

The peptide dual agonist according to claim 5, wherein said peptide is modified by attaching at least one fatty acid molecule at one or more lysine residues.

### Claim 7 (depends on 5)

The peptide dual agonist according to claim 5, wherein said fatty acid molecule is a monoacyl fatty acid molecule, comprising one fatty acid.

### Claim 8 (depends on 5)

The peptide dual agonist according to claim 5, wherein said fatty acid molecule is a diacyl fatty acid molecule.

### Claim 9 (depends on 5)

The peptide dual agonist according to claim 5, wherein said fatty acid molecule comprises an acyl group of the formula CH3(CH2)nCO—, wherein n in an integer from 4 to 24.

### Claim 10 (depends on 9)

The peptide dual agonist according to claim 9, wherein said fatty acid molecule comprises an acyl group selected from the group consisting of: CH3(CH2)10CO-(lauryl, C12), CH3(CH2)12CO— (myristoyl, C14), CH3(CH2)14O— (palmitoyl, C16) and CH3(CH2)16CO— (stearyl, C18).

### Claim 11 (depends on 5)

The peptide dual agonist according to claim 5, said peptide comprising a peptide selected from the group consisting of:
(SEQ ID NO: 18)
H(C16/1)ADGTFISDYSTILDNLAARDFINWLIQTKITK,
(SEQ ID NO: 18)
HADGTFISDYSTILDNLAARDFINWLIQTK(C12/30)ITK,
(SEQ ID NO: 18)
HADGTFISDYSTILDNLAARDFINWLIQTK(C16/30)ITK,
(SEQ ID NO: 18)
HADGTFISDYSTILDNLAARDFINWLIQTKITK(C12/33),
(SEQ ID NO: 18)
HADGTFISDYSTILDNLAARDFINWLIQTKITK(C16/33),
(SEQ ID NO: 19)
HADGTFISDYSTILDNLAARDFINWLIQTKGK(C12/32)K,
(SEQ ID NO: 19)
HADGTFISDYSTILDNLAARDFINWLIQTKGK(C16/32)K,
(SEQ ID NO: 26)
HADGTFSSDYSTILDNLAAK(C16/20)DFINWLIQTKITD,
(SEQ ID NO: 13)
H(C16/1)ADGTFSSDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 13)
HADGTFSSDYSTILDNLAARDFINWLIQTK(C16/30)ITD,
and a functional variant of any thereof having 1 or 2 individual amino acid substitutions, wherein said functional variant binds to and activates the GIPR and the GLP-2R.

### Claim 12 (depends on 1)

The peptide dual agonist according to claim 1, wherein said peptide is C-terminally amidated (—NH2) and/or wherein said peptide is N-terminally acetylated (COCH3).

### Claim 13 (depends on 1)

The peptide dual agonist according to claim 1, wherein said peptide
a. binds to GIPR and GLP2R, and/or
b. activates GIPR and GLP2R, and/or
c. stimulates GIPR- and GLP2R-mediated cAMP production, and/or
d. inhibits bone resorption, and/or
e. stimulates bone formation.

### Claim 14 (depends on 1)

The peptide dual agonist according to claim 1, wherein said peptide is capable of
a. activating the GIPR with an efficacy (Emax values) which is at least 65% of the efficacy by which native GIP activates the GIPR, and
b. activating the GLP2R with an efficacy (Emax values) which is at least 65% of the efficacy by which native GLP-2 activates the GLP2R.

### Claim 15

A method of inhibiting bone resorption and stimulating bone formation comprising administering a therapeutically effective amount of a peptide dual agonist of the GIPR and of the GLP2R, said peptide comprising
(SEQ ID NO: 21)
HX20X21GTFISDYSTILDNLAARD
FX22NWLX23X24X25KX26X27X28,
wherein X20 is selected from A, V and G,
X21 is selected from D and E,
X22 is selected from I and V,
X23 is selected from I and L,
X24 is selected from Q and A,
X25 is selected from T and Q,
X26 is selected from I and G,
X27 is selected from T and K, and
X28 is selected from D and K,
or a functional variant thereof having 1, 2, 3 or 4 individual amino acid substitutions, wherein said functional variant comprises substitution of 0, 1, or 2 of amino acids 5 to 11 of SEQ ID NO:21, and wherein said functional variant binds to and activates the GI PR and the GLP-2R.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said peptide comprises a sequence selected from the group consisting of:
a)
(SEQ ID NO: 11)
HGDGTFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 13)
HADGTFSSDYSTILDNLAARDFINWLIQTKITD,
and a functional variant of either thereof having 1 or 2 individual amino acid substitutions;
b)
(SEQ ID NO: 3)
HADGTFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 4)
HAEGSFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 6)
HAEGTFISDMNTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 12)
HVDGTFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 14)
HADGTFIDDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 15)
HADGTFISEYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 26)
HADGTFSSDYSTILDNLAAKDFINWLIQTKITD,
and a functional variant of any thereof having 1, 2 or 3 individual amino acid substitutions;
c)
(SEQ ID NO: 1)
HAEGTFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 2)
HAEGTFISDYSTILDNLAARDFINWLIQTKITDNDWKHNITQ,
(SEQ ID NO: 16)
HADGTFISDYSTILDNLAARDFINWLIQTKGTD,
(SEQ ID NO: 17)
HADGTFISDYSTILDNLAARDFINWLIQTKIKD,
(SEQ ID NO: 18)
HADGTFISDYSTILDNLAARDFINWLIQTKITK,
and a functional variant of any thereof having 1, 2, 3 or 4 individual amino acid substitutions;
d)
(SEQ ID NO: 27)
HADGTFISDYSKILDNLAARDFINWLIQTKITK,
(SEQ ID NO: 28)
HADGTFISDYSTIKDNLAARDFINWLIQTKITK,
(SEQ ID NO: 29)
HADGTFISDYSTILDKLAARDFINWLIQTKITK,
(SEQ ID NO: 30)
HADGTFISDYSTILDNLKARDFINWLIQTKITK,
(SEQ ID NO: 31)
HADGTFISDYSTILDNLAAKDFINWLIQTKITK,
(SEQ ID NO: 32)
HADGTFISDYSTILDNLAARDFINWLIQTKGKKNDWKHNITQ,
and a functional variant of any thereof having 1, 2, 3, 4 or 5 individual amino acid substitutions; and
e)
(SEQ ID NO: 7)
HAEGTFISDYSIAMDKLAARDFINWLIQTKITD
(SEQ ID NO: 8)
HAEGTFISDYSTILDNIHQQDFINWLIQTKITD
(SEQ ID NO: 9)
HAEGTFISDYSTILDNLAARDFVNWLLAQKITD,
(SEQ ID NO: 10)
HAEGTFISDYSTILDNLAARDFINWLIQTKGKK,
(SEQ ID NO: 19)
HADGTFISDYSTILDNLAARDFINWLIQTKGKK,
and a functional variant of any thereof having 1, 2, 3, 4, 5 or 6 individual amino acid substitutions,
wherein said functional variant comprises substitution of 0, 1, or 2 of amino acids 5 to 11 of SEQ ID NO:21, and wherein said functional variant binds to and activates the GIPR and the GLP-2R.

### Claim 17 (depends on 15)

The method according to claim 15, wherein said peptide is capable of
a. activating the GIPR with an efficacy (Emax values) which is at least 65% of the efficacy by which native GIP activates the GIPR, and
b. activating the GLP2R with an efficacy (Emax values) which is at least 65% of the efficacy by which native GLP-2 activates the GLP2R.

### Claim 18

A method treating a bone disorder comprising administering a therapeutically effective amount of a peptide dual agonist of the GIPR and of the GLP2R, said peptide comprising the sequence
(SEQ ID NO: 21)
HX20X21GTFISDYSTILDNLAARDF
X22NWLX23X24X25KX26X27X28,
wherein X20 is selected from A, V and G,
X21 is selected from D and E,
X22 is selected from I and V,
X23 is selected from I and L,
X24 is selected from Q and A,
X25 is selected from T and Q,
X26 is selected from I and G,
X27 is selected from T and K, and
X28 is selected from D and K,
or a functional variant thereof having 1, 2, 3 or 4 individual amino acid substitutions, wherein said functional variant comprises substitution of 0, 1, or 2 of amino acids 5 to 11 of SEQ ID NO:21, and wherein said functional variant binds to and activates the GIPR and the GLP-2R.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said bone disorder is selected from the group consisting of: osteopenia, osteoporosis, severe osteoporosis, osteomalacia, rickets, osteitis fibrosa cystica (OFC) and Paget's disease of bone.

### Claim 20 (depends on 18)

The method according to claim 18, wherein said peptide comprises or consists of a sequence selected from the group consisting of:
a)
(SEQ ID NO: 11)
HGDGTFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 13)
HADGTFSSDYSTILDNLAARDFINWLIQTKITD,
and a functional variant of either thereof having 1 or 2 individual amino acid substitutions;
b)
(SEQ ID NO: 3)
HADGTFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 4)
HAEGSFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 6)
HAEGTFISDMNTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 12)
HVDGTFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 14)
HADGTFIDDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 15)
HADGTFISEYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 26)
HADGTFSSDYSTILDNLAAKDFINWLIQTKITD,
and a functional variant of any thereof having 1, 2 or 3 individual amino acid substitutions;
c)
(SEQ ID NO: 1)
HAEGTFISDYSTILDNLAARDFINWLIQTKITD,
(SEQ ID NO: 2)
HAEGTFISDYSTILDNLAARDFINWLIQTKITDNDWKHNITQ,
(SEQ ID NO: 16)
HADGTFISDYSTILDNLAARDFINWLIQTKGTD,
(SEQ ID NO: 17)
HADGTFISDYSTILDNLAARDFINWLIQTKIKD,
(SEQ ID NO: 18)
HADGTFISDYSTILDNLAARDFINWLIQTKITK,
and a functional variant of any thereof having 1, 2, 3 or 4 individual amino acid substitutions;
d)
(SEQ ID NO: 27)
HADGTFISDYSKILDNLAARDFINWLIQTKITK,
(SEQ ID NO: 28)
HADGTFISDYSTIKDNLAARDFINWLIQTKITK,
(SEQ ID NO: 29)
HADGTFISDYSTILDKLAARDFINWLIQTKITK,
(SEQ ID NO: 30)
HADGTFISDYSTILDNLKARDFINWLIQTKITK,
(SEQ ID NO: 31)
HADGTFISDYSTILDNLAAKDFINWLIQTKITK,
(SEQ ID NO: 32)
HADGTFISDYSTILDNLAARDFINWLIQTKGKKNDWKHNITQ,
and a functional variant of any thereof having 1, 2, 3, 4 or 5 individual amino acid substitutions; and
e)
(SEQ ID NO: 7)
HAEGTFISDYSIAMDKLAARDFINWLIQTKITD
(SEQ ID NO: 8)
HAEGTFISDYSTILDNIHQQDFINWLIQTKITD
(SEQ ID NO: 9)
HAEGTFISDYSTILDNLAARDFVNWLLAQKITD,
(SEQ ID NO: 10)
HAEGTFISDYSTILDNLAARDFINWLIQTKGKK,
(SEQ ID NO: 19)
HADGTFISDYSTILDNLAARDFINWLIQTKGKK,
and a functional variant of any thereof having 1, 2, 3, 4, 5 or 6 individual amino acid substitutions,
wherein said functional variant comprises substitution of 0, 1, or 2 of amino acids 5 to 11 of SEQ ID NO:21, and wherein said functional variant binds to and activates the GIPR and the GLP-2R.
